Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, ...
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated ...
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly ...
The annual Youth LEGO Build Competition, hosted by Tahlequah Area Habitat for Humanity, is returning this summer with major expansions designed to welcome more builders, more families, and greater ...
+ Recent think-answer approaches in VLMs, such as Qwen3-VL-Thinking, boost reasoning performance by + leveraging intermediate thinking steps before the final answer, but their computational cost ...
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus ...
As more than 40 former University of Tulsa basketball figures reunited for the annual Legends Day game, the Tulsa Golden Hurricane defeated last-place UTSA 100-74 in an American Conference contest at ...
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results